Literature DB >> 11062203

Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii.

A Giacometti1, O Cirioni, M S Del Prete, F Barchiesi, A M Paggi, E Petrelli, G Scalise.   

Abstract

The in vitro activity of buforin II, cecropin P1, indolicidin, magainin II and ranalexin, alone and in combination with eight clinically used antimicrobial agents was investigated against 12 multidrug-resistant strains of Acinetobacter baumannii isolated from immunocompromised patients. Antimicrobial activities were measured by MIC, MBC and viable count. The peptides had a varied range of inhibitory values: overall, the organisms were more susceptible to buforin II (MIC range 0.25-16 mg/L), cecropin P1 (0.50-32 mg/L) and magainin II (0.50-16 mg/L). Synergy occurred when magainin II was combined with beta-lactam antibiotics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062203     DOI: 10.1093/jac/46.5.807

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 2.  Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance.

Authors:  Lucía Fernández; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

3.  Acinetobacter baumannii: A Brief Account of Mechanisms of Multidrug Resistance and Current and Future Therapeutic Management.

Authors:  Harmanjit Singh; Pugazhenthan Thangaraj; Amitava Chakrabarti
Journal:  J Clin Diagn Res       Date:  2013-11-10

4.  Activities of polymyxin B and cecropin A-,melittin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii.

Authors:  José María Saugar; Teresa Alarcón; Susana López-Hernández; Manuel López-Brea; David Andreu; Luis Rivas
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  Human salivary mucin MUC7 12-mer-L and 12-mer-D peptides: antifungal activity in saliva, enhancement of activity with protease inhibitor cocktail or EDTA, and cytotoxicity to human cells.

Authors:  Guo-Xian Wei; Libuse A Bobek
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii.

Authors:  Madhuri M Sopirala; Julie E Mangino; Wondwossen A Gebreyes; Beth Biller; Tammy Bannerman; Joan-Miquel Balada-Llasat; Preeti Pancholi
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

Review 7.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

8.  In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  João Pires; Thissa N Siriwardena; Michaela Stach; Regula Tinguely; Sara Kasraian; Francesco Luzzaro; Stephen L Leib; Tamis Darbre; Jean-Louis Reymond; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

9.  The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace.

Authors:  Ignasi Roca; Paula Espinal; Xavier Vila-Farrés; Jordi Vila
Journal:  Front Microbiol       Date:  2012-04-23       Impact factor: 5.640

10.  Bactericidal Activity of a Self-Biodegradable Lysine-Containing Dendrimer against Clinical Isolates of Acinetobacter Genus.

Authors:  Silvana Alfei; Debora Caviglia; Gabriella Piatti; Guendalina Zuccari; Anna Maria Schito
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.